Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

Citations Over TimeTop 1% of 2014 papers

Abstract

Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty-two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer-associated genes, using ion torrent semiconductor-based next-generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN-associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92%) of IPMNs. GNAS was mutated in 38/48 (79%) IPMNs, KRAS in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low-frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10% and 6%) were only observed in high-grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN-associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN-associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next-generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms.

Related Papers

• → Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development(2011)771 cited
• → Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression(2017)38 cited
• → Clinicopathological implications of GNAS in Ewing sarcoma(2016)1 cited
• → ID: 3522273 ASSESSING KRAS/GNAS AND BIOLOGIC BEHAVIOR USING MOLECULAR DNA ANALYSIS IN CHARACTERIZING PRE-MALIGNANT PANCREATIC CYSTS(2021)
• → Recognition of GNAS and KRAS mutations in endoscopic ultrasound – fine needle aspiration (EUS-FNA) fluid samples from the main pancreatic duct (MPD) accurately discriminates intraductal papillary mucinous neoplasm (IPMN) from benign conditions with MPD dilatation(2023)